BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 14523465)

  • 1. High incidence of trisomies 1q, 9q, and 11q in multiple myeloma: results from a comprehensive molecular cytogenetic analysis.
    Liebisch P; Wendl C; Wellmann A; Kröber A; Schilling G; Goldschmidt H; Einsele H; Straka C; Bentz M; Stilgenbauer S; Döhner H
    Leukemia; 2003 Dec; 17(12):2535-7. PubMed ID: 14523465
    [No Abstract]   [Full Text] [Related]  

  • 2. Duplication of chromosome arms 9q and 11q: evidence for a novel, 14q32 translocation-independent pathogenetic pathway in multiple myeloma.
    Liebisch P; Scheck D; Erné SA; Wellmann A; Wendl C; Janczik S; Kolmus S; Kröber A; Einsele H; Straka C; Goldschmidt H; Benner A; Stilgenbauer S; Döhner H
    Genes Chromosomes Cancer; 2005 Jan; 42(1):78-81. PubMed ID: 15390182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Translocation (11;14)(q13;q32) and partial trisomy 1q in a case of multiple myeloma.
    Kwong YL; Lie AK; Chan LC
    Am J Hematol; 1993 Nov; 44(3):212-3. PubMed ID: 8213777
    [No Abstract]   [Full Text] [Related]  

  • 4. Correlation between cytogenetic abnormalities and disease characteristics in multiple myeloma: monosomy of chromosome 13 and structural abnormalities of 11q are associated with a high percentage of S-phase plasma cells.
    Gutiérrez NC; Hernández JM; García JL; Almeida J; Mateo G; González MI; Hernández J; Fernández-Calvo J; San Miguel JF
    Haematologica; 2000 Nov; 85(11):1146-52. PubMed ID: 11064466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma.
    Sawyer JR
    Cancer Genet; 2011 Jan; 204(1):3-12. PubMed ID: 21356186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel translocation t(3;11)(p21;q24) in multiple myeloma characterised by FISH.
    Smith A; de Lambert R; Robson L
    Ann Genet; 1999; 42(4):221-4. PubMed ID: 10674162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High incidence and intraclonal heterogeneity of chromosome 11 aberrations in patients with newly diagnosed multiple myeloma detected by multiprobe interphase FISH.
    Cremer FW; Kartal M; Hose D; Bila J; Buck I; Bellos F; Raab MS; Brough M; Moebus A; Hager HD; Goldschmidt H; Moos M; Bartram CR; Jauch A
    Cancer Genet Cytogenet; 2005 Sep; 161(2):116-24. PubMed ID: 16102581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of chromosome numerical changes in multiple myeloma: fluorescence in situ hybridization analysis using 15 chromosome-specific probes.
    Tabernero D; San Miguel JF; Garcia-Sanz M; Nájera L; García-Isidoro M; Peréz-Simon JA; Gonzalez M; Wiegant J; Raap AK; Orfão A
    Am J Pathol; 1996 Jul; 149(1):153-61. PubMed ID: 8686739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
    Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
    Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myelodysplastic syndrome with isochromosome 5p and trisomy 8 after treatment of a multiple myeloma.
    Jimenez-Sousa MA; Ferro MT; Talavera M; Villalon C; Cabello P; Laraña J; Herrera P; Garcia Sagredo JM
    Cancer Genet Cytogenet; 2010 Dec; 203(2):345-7. PubMed ID: 21156257
    [No Abstract]   [Full Text] [Related]  

  • 11. Sequential loss of heterozygosity at microsatellite motifs in preinvasive and invasive head and neck squamous carcinoma.
    el-Naggar AK; Hurr K; Batsakis JG; Luna MA; Goepfert H; Huff V
    Cancer Res; 1995 Jun; 55(12):2656-9. PubMed ID: 7780981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia.
    Rasillo A; Tabernero MD; Sánchez ML; Pérez de Andrés M; Martín Ayuso M; Hernández J; Moro MJ; Fernández-Calvo J; Sayagués JM; Bortoluci A; San Miguel JF; Orfao A
    Cancer; 2003 Feb; 97(3):601-9. PubMed ID: 12548602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Multicolor spectral karyotyping (SKY) and its application to the cytogenetic diagnosis of multiple myeloma].
    Cigudosa JC; Calasanz MJ; García Miranda JL
    Sangre (Barc); 1999 Aug; 44(4):301-4. PubMed ID: 10589283
    [No Abstract]   [Full Text] [Related]  

  • 14. Gain of chromosome arm 1q in patients in relapse and progression of multiple myeloma.
    Balcárková J; Urbánková H; Scudla V; Holzerová M; Bacovský J; Indrák K; Jarosová M
    Cancer Genet Cytogenet; 2009 Jul; 192(2):68-72. PubMed ID: 19596256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of trisomy 12, del(13q), del(17p), and del(11q) on the immunophenotype, DNA ploidy status, and proliferative rate of leukemic B-cells in chronic lymphocytic leukemia.
    Quijano S; López A; Rasillo A; Sayagués JM; Barrena S; Sánchez ML; Teodosio C; Giraldo P; Giralt M; Pérez MC; Romero M; Perdiguer L; Orfao A
    Cytometry B Clin Cytom; 2008 May; 74(3):139-49. PubMed ID: 18061951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chromosome findings in multiple myeloma].
    Suzuki K
    Nihon Rinsho; 1995 Mar; 53(3):568-73. PubMed ID: 7699887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Correlation between chromosome 13q14 deletion and 1q abnormality in multiple myeloma].
    Chen LJ; Li JY; Zhu Y; Wang XW; Qiu HR; Yang RF; Xu W; Xu JR; Lu H
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2009 Feb; 26(1):102-5. PubMed ID: 19199264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics.
    Cremer FW; Bila J; Buck I; Kartal M; Hose D; Ittrich C; Benner A; Raab MS; Theil AC; Moos M; Goldschmidt H; Bartram CR; Jauch A
    Genes Chromosomes Cancer; 2005 Oct; 44(2):194-203. PubMed ID: 16001433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural rearrangements of trisomies are a risk marker of clinical progression in hyperdiploid multiple myeloma.
    Alfaro R; Rosell J; Durán MA; Puget G; Besalduch J; Galán P; Vallés A; Bernués M
    Anticancer Res; 2011 May; 31(5):1599-602. PubMed ID: 21617215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Marker chromosomes as a product of familial translocation (11;22) identified with molecular cytogenetic methods].
    Stankiewicz P; Korniszewski L; Bocian E; Stańczak H
    Pediatr Pol; 1996 Mar; 71(3):241-5. PubMed ID: 8966096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.